ACTRN12614000393651已完成未知
Autonomous paramedic delivered pre-hospital thrombolysis: A new approach in the treatment of ST-elevation myocardial infarction patients to determine if this new model may improve treatment delivery times, patient outcomes and reduce hospital admission times.
Auckland University of Technology (AUT)0 个研究点目标入组 108 人开始时间: 2014年4月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •a) The retrospective cohort (n = 54) will include patients at/or greater than 18 years of age who have received paramedic-delivered PHT under physician authorisation in the Northland and Hawkes Bay regions since this historic PHT model was established in 2008.
- •b) The prospective cohort (n = 54) will include; patients at/or greater than 18 years of age who receive autonomous paramedic-delivered PHT; or those who have been considered for the treatment over a 20 month period; in the Northland and Hawkes Bay regions; and in line with protocol criteria. In addition, during this 20-month prospective period, the study will also investigate all patients at/or greater than 18 years of age transported by paramedics without PHT treatment in the same regions, but who went on to receive in-hospital thrombolysis following an in-hospital diagnosis of STEMI.
排除标准
- •Key patient exclusion criteria is essentially those that do not meet our inclusion criteria for either the historic or prospective cohort.
研究者
相似试验
已完成
3 期
Efficacy and safety in AryoTrust™ (Aryogen trastuzumab) vs Herceptin® (Genentech/Roche trastuzumab), a non inferiority trialbreast cancer patients with HER2-positive.Malignant neoplasm of breastIRCT201606226135N7Aryogen pharmed Company108
招募中
1 期
Effects of a new topical treatment, Victorhy, in patients with severe hand hyperhidrosisCTIS2023-507114-27-00Dryox Health S.L.60
已完成
不适用
A randomized, vehicle-controlled, double-blind, Phase I/IIa, multiple-dose, multiple-cohort, Proof of Concept study in Healthy Volunteers and Patients with Cutaneous T-cell Lymphoma to characterize the safety, efficacy, and pharmacodynamics of topical bimiralisibblood cancer affecting the skin10025321NL-OMON48135Piqur Therapeutics AG24
进行中（未招募）
1 期
Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)Elevated liver enzymesneutropeniaInflammatory and Immune System - Rheumatoid arthritisthrombocytopeniaACTRN12618000859280Mycenax Biotech Inc.190
进行中（未招募）
不适用
A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LDE225 (a specific Smoothened inhibitor) on sporadic superficial skin basal cell carcinomassporadic superficial and nodular skin basal cell carcinomasMedDRA version: 12.0Level: LLTClassification code 10042503Term: Superficial basal cell carcinomaEUCTR2009-013665-26-ATovartis Pharma48